JP2014502276A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502276A5
JP2014502276A5 JP2013542218A JP2013542218A JP2014502276A5 JP 2014502276 A5 JP2014502276 A5 JP 2014502276A5 JP 2013542218 A JP2013542218 A JP 2013542218A JP 2013542218 A JP2013542218 A JP 2013542218A JP 2014502276 A5 JP2014502276 A5 JP 2014502276A5
Authority
JP
Japan
Prior art keywords
seq
antibody
apoe
amino acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063121 external-priority patent/WO2012075422A2/en
Publication of JP2014502276A publication Critical patent/JP2014502276A/ja
Publication of JP2014502276A5 publication Critical patent/JP2014502276A5/ja
Pending legal-status Critical Current

Links

JP2013542218A 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法 Pending JP2014502276A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (2)

Publication Number Publication Date
JP2014502276A JP2014502276A (ja) 2014-01-30
JP2014502276A5 true JP2014502276A5 (cg-RX-API-DMAC7.html) 2015-01-22

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542218A Pending JP2014502276A (ja) 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法

Country Status (14)

Country Link
US (2) US20140037638A1 (cg-RX-API-DMAC7.html)
EP (1) EP2646053A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014502276A (cg-RX-API-DMAC7.html)
KR (1) KR20140017513A (cg-RX-API-DMAC7.html)
CN (1) CN103338786A (cg-RX-API-DMAC7.html)
AU (1) AU2011336360A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013013723A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819679A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013006116A (cg-RX-API-DMAC7.html)
NZ (1) NZ611614A (cg-RX-API-DMAC7.html)
RU (1) RU2013130002A (cg-RX-API-DMAC7.html)
SG (1) SG190952A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012075422A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201303996B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CA2962969C (en) 2014-09-30 2023-03-21 Washington University Tau kinetic measurements
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
WO2018081642A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク,インコーポレーテツド フィブロネクチンiii型ドメインに対する抗原結合領域及びその使用方法
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
EP4419552A4 (en) * 2021-10-19 2025-09-24 Bioatla Inc CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES
AU2023399623A1 (en) * 2022-11-30 2025-07-03 Bio-Techne Corporation Natural killer cell engagers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
EP1687336A2 (en) * 2003-11-28 2006-08-09 AstraZeneca AB Antibodies
AU2005228764A1 (en) * 2004-03-30 2005-10-13 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
CA2643048A1 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2791648A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2014502276A5 (cg-RX-API-DMAC7.html)
JP2009530423A5 (cg-RX-API-DMAC7.html)
Antonios et al. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
US11926660B2 (en) Anti-ApoE antibodies
JP2010506596A5 (cg-RX-API-DMAC7.html)
JP2010526028A5 (cg-RX-API-DMAC7.html)
JP2019527194A5 (cg-RX-API-DMAC7.html)
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
JP2015533795A5 (cg-RX-API-DMAC7.html)
RU2017137872A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
JP2017536102A5 (cg-RX-API-DMAC7.html)
JP2020517740A5 (cg-RX-API-DMAC7.html)
JP2014503189A5 (cg-RX-API-DMAC7.html)
JP2013538796A5 (cg-RX-API-DMAC7.html)
JP2018505651A5 (cg-RX-API-DMAC7.html)
RU2013130002A (ru) Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками
JP2012504634A5 (cg-RX-API-DMAC7.html)
JP2013198490A5 (cg-RX-API-DMAC7.html)
JP2014509510A5 (cg-RX-API-DMAC7.html)
JP2010507594A5 (cg-RX-API-DMAC7.html)
JP2020536532A5 (cg-RX-API-DMAC7.html)
JP2016525502A5 (cg-RX-API-DMAC7.html)
PE20061152A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP2013538553A5 (cg-RX-API-DMAC7.html)
HRP20191342T1 (hr) Anti-phf-tau antitijela i njihove upotrebe